Ki Young Sohn

USPTO Granted Patents = 11 (Patent Applications = 10)

CIPO Patents = 5 (Patent Applications = 6)

EPO Patents = 8 (Patent Applications = 16)

Average Co-Inventor Count = 3.8

ph-index = 1

Company Filing History:

11 out of 22

Enzychem Lifesciences Corporation

patents

3 out of 321

Korea Research Institute of Bioscience and Biotechnology

patents

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12297163 - Glycerol derivative, preparation method therefor, and immunomodulator comprising same as effective ingredient (2025-05-13),

2. 12187672 - 1,2-diacylglycerol compound, preparation method therefor, and immunomodulator containing same as active ingredient (2025-01-07),

3. 12076307 - Compositions for prevention or treatment of acute radiation syndrome and other radiation exposure (2024-09-03),

4. 11590096 - Compositions for prevention or treatment of acute radiation syndrome and other radiation exposure (2023-02-28),

5. 11192864 - Method for producing calcobutrol (2021-12-07),

6. 11135193 - Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma (2021-10-05),

7. 10765655 - Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating chronic obstructive pulmonary disease (2020-09-08),

8. 10653657 - Method for treating hemolytic uremic syndrome (2020-05-19),

9. 10555923 - Method for treating paroxysmal nocturnal hemoglobinuria (2020-02-11),

10. 10098864 - Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma (2018-10-16),

11. 9763908 - Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating atopic dermatitis (2017-09-19),

Title: Ki Young Sohn: Innovator in Immunomodulation

Introduction

Ki Young Sohn is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of immunomodulation, holding a total of 11 patents. His work focuses on developing novel compounds that can improve, prevent, or treat inflammation-related diseases.

Latest Patents

Among his latest patents is a glycerol derivative that is effective in treating inflammation-related diseases by inhibiting the overexpression of various inflammatory cytokines such as IL-4 and IL-6. This patent also includes a preparation method for the glycerol derivative and an immunomodulator containing it as an active ingredient. Another notable patent involves a novel 1,2-diacylglycerol compound, which similarly targets inflammation-related diseases by inhibiting inflammatory cytokines and chemokines. This compound is also accompanied by a preparation method and an immunomodulator that utilizes it as an active ingredient.

Career Highlights

Ki Young Sohn has worked with notable organizations such as Enzychem Lifesciences Corporation and the Korea Research Institute of Bioscience and Biotechnology. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative solutions in the field of immunology.

Collaborations

He has collaborated with esteemed colleagues, including Jae Wha Kim and Sun Young Yoon, to further enhance his research efforts and patent developments.

Conclusion

Ki Young Sohn's innovative work in immunomodulation and his impressive portfolio of patents highlight his significant contributions to medical science. His research continues to pave the way for advancements in treating inflammation-related diseases.

This text is generated by artificial intelligence and may not be accurate.